Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 473,621

Document Document Title
WO/2018/132419A1
Examples described herein relate to coconut residue pulp compositions, methods of making a coconut residue pulp composition, and products having a coconut residue pulp composition.  
WO/2018/129647A1
A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containin...  
WO/2018/132766A1
The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and ...  
WO/2018/132066A1
Disclosed are compounds having the following formula: (I) wherein R is an alkane chain having between 8 and 20 carbon atoms, and A is one or more anions having a total charge of -2; or R is a quaternary amine having the following formula...  
WO/2018/132372A1
Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.  
WO/2018/131659A1
An immunotherapeutic agent containing a heterocyclic compound represented by general formula (I) or a metabolite or pharmaceutically acceptable salt thereof as an active ingredient.  
WO/2018/130943A1
The present invention relates to an oral pharmaceutical composition, particularly a tablet, comprising an active ingredient lurasidone or its pharmaceutically acceptable salt(s) or solvate(s) thereof and one or more pharmaceutical excipi...  
WO/2018/132759A1
The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.  
WO/2018/132531A1
Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).  
WO/2018/132369A1
The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.  
WO/2018/130537A1
The present invention is directed to cell-protective, in particular, cardio- and renal-protective organic compounds, preferably to organic compounds that inhibit substrate phosphorylation by the G-protein-coupled receptor kinase 2 (GRK2,...  
WO/2018/131950A1
The present invention relates to a carbocyclic nucleoside derivative represented by chemical formula A or a pharmaceutically acceptable salt thereof, and an antiviral agent comprising the same.  
WO/2018/130140A1
A novel deuterated urea compound, specifically relating to a compound represent by the formula (I), pharmacologically acceptable salts thereof, preparation method therefor, and a pharmaceutical composition containing the compounds. Also ...  
WO/2018/129904A1
Disclosed are a benzodiazepine alkaloid compound and a pharmaceutically acceptable salt thereof, the structure of the compound being shown in general formula (I). In formula (I), R1, R2 and R3 independently are hydrogen, C1 ~4 alkyl or C...  
WO/2018/131643A1
The present invention is a capsule which contains, as the capsule contents, pyrroloquinoline quinone or a salt thereof, a branched chain amino acid, and an edible fat or oil or a cyclodextrin.  
WO/2018/132383A1
Provided are agents that disrupt CRY1-CLOCK-BMAL1 ternary complexes. In certain aspects, the agents bind to the secondary pocket of CRY1 and inhibit interaction between the secondary pocket and the PAS-B domain of CLOCK, to disrupt CRY1-...  
WO/2018/130868A1
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment a...  
WO/2018/130948A1
An intranasal composition as unit dosage, comprising tapentadol or a pharmaceutically acceptable salt thereof in an amount that is equivalent to about 19.3 mg tapentadol free base; and at least one nasal carrier. After intranasal adminis...  
WO/2018/130659A1
The invention relates to apolypeptide capable of binding to TGF-β for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-β, wherein said polypeptide is capable of inhibiting theinteraction of T...  
WO/2018/130184A1
The present invention relates to a 1,2,4-triazine-3-amine derivative, a preparation therefor, and use thereof in medicine. Specifically, the present invention relates to a 1,2,4-triazine-3-amine derivative as represented by general formu...  
WO/2018/132326A1
Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hema...  
WO/2018/130063A1
The present invention provides an (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, which has diffraction peaks when 2θ is 12.423±0.2°, 16.465±0.2°, 17.344±0.2°, 21.889±0.2°, and 25.054±0.2°. The present invention can p...  
WO/2018/131717A1
A dough which has excellent formability even while containing a polymer material having ion adsorption capacity or ion exchange capacity, a baked confectionery which is the baked product of said dough, a pharmaceutical composition formed...  
WO/2018/131963A1
Disclosed is an effect of ginsenoside compound K for inhibiting cytotoxic anticancer drug side-effects such as gastrointestinal disorders, bone marrow dysfunction, liver, kidney, and pancreatic dysfunction and the like.  
WO/2018/131930A1
The present invention relates to a feed composition for preventing or treating coccidiosis; a pharmaceutical composition; an Eimeria tenella protozoacidal composition; and a method for preventing or treating coccidiosis, comprising aneth...  
WO/2018/130207A1
The present invention pertains to the field of pharmaceutical chemicals, and discloses a 4,4-diphenyl piperidine compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition using the same, and a use thereof. Spec...  
WO/2018/130390A1
The present invention is based on the loading of a hydrophilic natural three-dimensional network made of cellulose nanofibers with lipid-based dermal carrier systems. Lipophilic or hardly water-soluble active substances both for cosmetic...  
WO/2018/132279A1
The invention relates generally to compounds of formula (I) that modulate the activity of TGFβR-l and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysre...  
WO/2018/130679A1
The present invention relates to a method for reducing CD95-mediated cell motility. To identify chemicals disrupting CD95/PLCγ1 interaction, the inventors screened a chemical library of EMA/FDA-approved molecules against a protein-fragm...  
WO/2018/130959A1
The present patent application concerns a composition for application on the hair and on the scalp, comprising 7-hydroxymatairesinol (HMR) in concentrations ranging from 2% to 10% by weight on the total weight of the composition, diols a...  
WO/2018/132732A1
Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide, where the conjugates have phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of de...  
WO/2018/130685A1
The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1)modulator, e.g. a HTR1antagonist.In addition the invention relates to a pharmace...  
WO/2018/132539A1
Provided are methods of increasing innate and adaptive immune activation in a human subject by administering a composition comprising the TLR7/8 agonist MED 19197, preferably via intratumoral injection into a cutaneous or subcutaneous tu...  
WO/2018/130863A1
The invention relates to promoting authopagy in the treatment or prevention of autophagy related disorders, such as various forms of cancer; neurodegenerative disease, diabetes, immune deficiency, infection by intracellular microbes, tis...  
WO/2018/129622A1
Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the can...  
WO/2018/130519A1
The present invention concerns medium molecular weight heparin (MMWH 10.5 kD) for prevention and treatment of venous thromboembolism in malignant disease.  
WO/2018/130625A1
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...  
WO/2018/130840A1
The invention relates to the treatment and/or prevention of cardiovascular disease, for example thromboembolic conditions, such as atherothrombotic disease. In particularly, the invention relates to an arginine methylation inhibitor ('Ar...  
WO/2018/130226A1
A crystal form CS4 and a crystal form CS9 of riociguat, and a preparation method and use thereof. The crystal form CS4 and the crystal form CS9 of riociguat have good solubility, high dissolution rate, good stability, and high purity, wh...  
WO/2018/132769A1
The present technology provides compounds according to Formula (I) as well as compositions including such compounds useful for the treatment of cancers such as non-small cell lung cancer, bladder cancer, or colon cancer.  
WO/2018/132518A1
Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells. In some embodiments, the methods include epigenetic and/or epigenomic ...  
WO/2018/132829A1
The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extra...  
WO/2018/132755A1
Retrotransposons, operating though human-specific neurological pathways, can contribute to environment, lifestyle, and/or age-related neurodegeneration by disrupting functional mitochondrial populations within neurons. The mitochondrial ...  
WO/2018/130951A1
Provided herein are chitosan-containing formulations, methods of making such formulations, and methods of using such formulations. Chitosan contemplated for use herein is preferably of high quality and its source is preferably of crustac...  
WO/2018/130345A1
The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in...  
WO/2018/130213A1
Disclosed are an imidazopyrazine compound, a preparation method therefor and use thereof. Specifically, disclosed are a compound having a structure as represented by formula (I), a pharmaceutically acceptable salt, a stereoisomer or a pr...  
WO/2018/131924A1
The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases, containing, as an active ingredient, a pyridinol derivative or a pharmaceutically acceptable salt thereof. A pyridinol derivati...  
WO/2018/132268A1
The present disclosure provides pharmaceutical agents, including those of the formula:(I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceu...  
WO/2018/132627A1
A composition and a method for improving the gastrointestinal (Gl) health of a human subject by promoting the activity of amylolytic and short-chain fatty acid (SCFA) producing (e.g. acetogenic and/or butyrogenic) microbes in the Gl syst...  
WO/2018/130584A1
The present invention relates to antisense oligonucleotides that are capable of modulating expression of NF-kB2 in a target cell. The oligonucleotides are complementary to mammalian NFKB2 pre-mRNA sequence. The present invention further ...  

Matches 1 - 50 out of 473,621